Dasgupta, A., Shukla, S.K., Vernucci, E., King, R.J., Abrego, J., Mulder, S.E., Mullen, N.J., Graves, G., Buettner, K., Thakur, R., Murthy, D., Attri, K.S., Wang, D., Chaika, N.V., Pacheco, C.G., Rai, I., Engle, D. D., Grandgenett, P. M., Punsoni, M., Reames, B.N., Teoh-Fitzgerald, M., Oberley-Deegan, R., Yu, F., Klute, K.A., Hollingsworth, M.A., Zimmerman, M.C., Mehla, K., Sadoshima, J., Tuveson, D. A., Singh, P.K. (July 2020) SIRT1-NOX4 Signaling Axis Regulates Cancer Cachexia. J Exp Med, 217 (7). e20190745. ISSN 0022-1007
PDF
jem_20190745.pdf - Published Version Download (6MB) |
Abstract
Approximately one third of cancer patients die due to complexities related to cachexia. However, the mechanisms of cachexia and the potential therapeutic interventions remain poorly studied. We observed a significant positive correlation between SIRT1 expression and muscle fiber cross-sectional area in pancreatic cancer patients. Rescuing Sirt1 expression by exogenous expression or pharmacological agents reverted cancer cell-induced myotube wasting in culture conditions and mouse models. RNA-seq and follow-up analyses showed cancer cell-mediated SIRT1 loss induced NF-κB signaling in cachectic muscles that enhanced the expression of FOXO transcription factors and NADPH oxidase 4 (Nox4), a key regulator of reactive oxygen species production. Additionally, we observed a negative correlation between NOX4 expression and skeletal muscle fiber cross-sectional area in pancreatic cancer patients. Knocking out Nox4 in skeletal muscles or pharmacological blockade of Nox4 activity abrogated tumor-induced cachexia in mice. Thus, we conclude that targeting the Sirt1-Nox4 axis in muscles is an effective therapeutic intervention for mitigating pancreatic cancer-induced cachexia.
Actions (login required)
Administrator's edit/view item |